10:25 AM EDT, 09/16/2024 (MT Newswires) -- Cullinan Therapeutics ( CGEM ) said Monday it filed an investigational new drug application to the US Food and Drug Administration to evaluate its CLN-978 to treat systemic lupus erythematosus, a chronic autoimmune disorder.

CLN-978 is a half-life extended CD19xCD3 bispecific T cell engager construct, the company said.

Price: 18.02, Change: +0.07, Percent Change: +0.36